AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 273: H734-H739, 1997;
0363-6135/97 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gao, H.
Right arrow Articles by Wilcox, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gao, H.
Right arrow Articles by Wilcox, C. S.

AJP - Heart and Circulatory Physiology, Vol 273, Issue 2 734-H739, Copyright © 1997 by American Physiological Society

ARTICLES

Sympathetic nervous system and hypertension during prolonged TxA2/PGH2 receptor activation in rats

H. Gao, W. J. Welch, G. F. DiBona and C. S. Wilcox
Division of Nephrology and Hypertension, Georgetown University Medical Center, Washington, District of Columbia, USA.

The thromboxane A2 (TxA2)/prostaglandin H2 (PGH2) receptor mimetic U-46619 (0.6 microgram.kg-1.min-1) was infused into conscious rats receiving a high-salt diet. U-46619 increased the mean arterial pressure (MAP) over 13 days by 25 +/- 2 mmHg, whereas the MAP of vehicle-infused controls did not change (-2 +/- 2 mmHg). In subgroups infused with U-46619, cardiac output was unchanged, whereas renal blood flow was reduced (before: 8.5 +/- 0.8; day 4: 5.7 +/- 0.7 ml/min; P < 0.01). Ifetroban (a specific TxA2/PGH2 receptor antagonist) reduced MAP to basal levels in the group receiving U-46619 when infused intravenously (1-100 micrograms/kg) but not intracerebroventricularly (1-100 ng/kg). Hexamethonium (10 mg/kg i.v., a ganglionic blocking agent) and prazosin (0.1 mg/kg, an alpha-adrenergic antagonist) decreased MAP significantly (P < 0.05) more in the experimental group (hexamethonium, U-46619: -55 +/- 3 vs. vehicle: -43 +/- 4 mmHg; and prazosin, U-46619: 28 +/- 3 vs. vehicle: 17 +/- 2 mmHg). In conclusion, hypertension during prolonged infusions of U-46619 into conscious, salt-loaded rats is accompanied by an increase in total and renal vascular resistance and is dependent on peripheral but not central TxA2/PGH2 receptors and on the autonomic and alpha 1-adrenergic peripheral sympathetic nervous systems.


This article has been cited by other articles:


Home page
 J. Physiol.Home page
L.-W. Fu, Z.-L. Guo, and J. C. Longhurst
Undiscovered role of endogenous thromboxane A2 in activation of cardiac sympathetic afferents during ischaemia
J. Physiol., July 1, 2008; 586(13): 3287 - 3300.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. J. Welch, K. Patel, P. Modlinger, M. Mendonca, N. Kawada, K. Dennehy, S. Aslam, and C. S. Wilcox
Roles of vasoconstrictor prostaglandins, COX-1 and -2, and AT1, AT2, and TP receptors in a rat model of early 2K,1C hypertension
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2644 - H2649.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
C. S. Wilcox and W. J. Welch
Thromboxane synthase and TP receptor mRNA in rat kidney and brain: effects of salt intake and ANG II
Am J Physiol Renal Physiol, March 1, 2003; 284(3): F525 - F531.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Kitiyakara, W. J. Welch, J. G. Verbalis, and C. S. Wilcox
Role of thromboxane receptors in the dipsogenic response to central angiotensin II
Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2002; 282(3): R865 - R869.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online